News - Page 140 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results Conference Call for Tuesday, November 16, 2021 at 8:30 AM ET

Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results Conference Call for Tuesday, November 16, 2021 at 8:30 AM ET

Post published:November 2, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia

Post published:November 2, 2021
Post category:Press Release

Read more about the article Cybin Hosting Research and Development Briefing on November 8, 2021

Cybin Hosting Research and Development Briefing on November 8, 2021

Post published:November 2, 2021
Post category:Press Release

Read more about the article Psychedelic Research Bulletin: October 2021

Psychedelic Research Bulletin: October 2021

Post published:November 2, 2021
Post category:Psychedelics Research Review

Read more about the article Small Pharma Reports Second Quarter Highlights

Small Pharma Reports Second Quarter Highlights

Post published:November 1, 2021
Post category:Press Release

Read more about the article atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort of Phase 2a Trial for Novel Treatment of Cognitive Impairment Associated with Schizophrenia

atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort of Phase 2a Trial for Novel Treatment of Cognitive Impairment Associated with Schizophrenia

Post published:November 1, 2021
Post category:Press Release

Read more about the article Red Light Holland Appoints New Chief Financial Officer

Red Light Holland Appoints New Chief Financial Officer

Post published:November 1, 2021
Post category:Press Release

Read more about the article PharmaDrug Expands Product Offering to Prepare for Potential Adult Use Market in Germany

PharmaDrug Expands Product Offering to Prepare for Potential Adult Use Market in Germany

Post published:November 1, 2021
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study

Post published:November 1, 2021
Post category:Press Release

Read more about the article Psychedelic Bulletin: MindMed Announces R(-)-MDMA Program; Psilocybin for Anxiety Study Secures Ethics Approval; UCL Joins the Renaissance

Psychedelic Bulletin: MindMed Announces R(-)-MDMA Program; Psilocybin for Anxiety Study Secures Ethics Approval; UCL Joins the Renaissance

Post published:October 29, 2021
Post category:Psychedelic Bulletin

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.